Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001558370-21-014453
Filing Date
2021-11-04
Accepted
2021-11-04 07:45:35
Documents
57
Period of Report
2021-09-30

Document Format Files

Seq Description Document Type Size
1 10-Q ettx-20210930x10q.htm   iXBRL 10-Q 1216820
2 EX-31.1 ettx-20210930xex31d1.htm EX-31.1 13546
3 EX-31.2 ettx-20210930xex31d2.htm EX-31.2 12847
4 EX-32.1 ettx-20210930xex32d1.htm EX-32.1 8771
  Complete submission text file 0001558370-21-014453.txt   5092319

Data Files

Seq Description Document Type Size
5 EX-101.SCH ettx-20210930.xsd EX-101.SCH 44697
6 EX-101.CAL ettx-20210930_cal.xml EX-101.CAL 36639
7 EX-101.DEF ettx-20210930_def.xml EX-101.DEF 153269
8 EX-101.LAB ettx-20210930_lab.xml EX-101.LAB 376292
9 EX-101.PRE ettx-20210930_pre.xml EX-101.PRE 283336
10 EXTRACTED XBRL INSTANCE DOCUMENT ettx-20210930x10q_htm.xml XML 812222
Mailing Address 35 GATEHOUSE DRIVE WALTHAM MA 02451
Business Address 35 GATEHOUSE DRIVE WALTHAM MA 02451 (781) 810-0120
Entasis Therapeutics Holdings Inc. (Filer) CIK: 0001724344 (see all company filings)

EIN.: 824592913 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-38670 | Film No.: 211378052
SIC: 2834 Pharmaceutical Preparations